NDAORALTABLET
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
TENEX (guanfacine hydrochloride) by Teva is clinical pharmacology guanfacine tablets, are an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central α 2 -adrenergic receptors. First approved in 1986.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TENEX (guanfacine hydrochloride) is an oral antihypertensive agent approved in 1986 that works by stimulating central α2-adrenergic receptors to reduce sympathetic nerve impulses. It decreases peripheral vascular resistance and heart rate, resulting in lower blood pressure in patients with mild to moderate hypertension. The drug is typically dosed once daily at bedtime, with effective doses ranging from 1–3 mg.
LOE Approaching
Product is in late-stage lifecycle (LOE approaching), suggesting smaller, maintenance-focused commercial teams rather than growth-phase expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Guanfacine tablets, are an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central α 2 -adrenergic receptors. By stimulating these receptors, guanfacine reduces sympathetic nerve impulses from the vasomotor center to the…
Worked on TENEX at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.